Market Place
Sourcing Support
Phase 2 fail sends OcuTerra`s eye drop dreams down the drain
14 Mar 2024 //
FIERCE BIOTECH
OcuTerra to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
OcuTerra Announces Last Patient Completes Final Visit in Nesvategrast
03 Jan 2024 //
BUSINESSWIRE
OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of OTT166
18 Jul 2023 //
BUSINESSWIRE
OcuTerra Appoints Bill Steinkrauss as Chief Financial Officer
01 Jun 2023 //
BUSINESSWIRE
OcuTerra Reports Publication of OTT166 Biological Activity Data from Ph1b Study
19 Oct 2022 //
BUSINESSWIRE
OcuTerra Begins Dosing in OTT166 PII DR:EAM Trial for Diabetic Retinopathy
02 Aug 2022 //
BUSINESSWIRE
OcuTerra Appoints Majid Anderesi, MD, as VP of Clinical and Medical Affairs
04 Apr 2022 //
BUSINESSWIRE
OcuTerra Appoints Barbara Ryan to Board of Directors
14 Dec 2021 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.